CN1274363C - Auxiliary therapeutic agent for C type hepatitis - Google Patents

Auxiliary therapeutic agent for C type hepatitis Download PDF

Info

Publication number
CN1274363C
CN1274363C CN 200310101281 CN200310101281A CN1274363C CN 1274363 C CN1274363 C CN 1274363C CN 200310101281 CN200310101281 CN 200310101281 CN 200310101281 A CN200310101281 A CN 200310101281A CN 1274363 C CN1274363 C CN 1274363C
Authority
CN
China
Prior art keywords
cordyceps
type hepatitis
therapeutical agent
auxiliary therapeutical
hepatitis
Prior art date
Application number
CN 200310101281
Other languages
Chinese (zh)
Other versions
CN1607003A (en
Inventor
柯万盛
Original Assignee
泰宗生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 泰宗生物科技股份有限公司 filed Critical 泰宗生物科技股份有限公司
Priority to CN 200310101281 priority Critical patent/CN1274363C/en
Publication of CN1607003A publication Critical patent/CN1607003A/en
Application granted granted Critical
Publication of CN1274363C publication Critical patent/CN1274363C/en

Links

Abstract

The present invention relates to an auxiliary therapeutic agent for hepatitis C, which is matched with a compound therapeutic method (interferon and Ribavirin) for treating hepatitis C. The present invention is composed of 50 to 90 of aweto and 10 to 50 of astragalus according to weight ratio. The auxiliary therapeutic agent can regulate the immune function of a patient with the hepatitis C and can kill viruses by matching the existing interferon therapeutic method, and thus, the curative effect on treating the hepatitis C can be improved.

Description

C type hepatitis auxiliary therapeutical agent
Technical field
The present invention relates to a kind ofly have the therapeutic agent of Cordyceps, Radix Astragali composition as auxiliary treatment C type hepatitis, its C type hepatitis combination therapy (interferon and Ribavirin) of can arranging in pairs or groups is to improve cure rate of C type hepatitis.
Background technology
Hepatitis C virus is a kind of RNA viruses, finds in 1989, is called non-a non-b hepatitis (Non-A in the past, Non-B hepatitis), cause by blood transfusion mostly, find this virus after, the reviewer before blood transfusion, whole blood screening all in advance, incidence rate declines to a great extent then.
C type hepatitis is respectively I, II, four kinds of genotype of III, IV according to the classification of okamotoShi, be mainly geno typeII in the C in Taiwan type hepatitis and account for 73%, secondly for typeIII account for 13% and typeIV account for 3%.Use interferon therapy C type hepatitis with more effective for III type and IV type, and relatively poor for II type and I type effect.The not good pact of viral Cl of independent use interferon therapy chronic hepatitis is 20-30% only, and therefore, the combination treatment that the whole world all adopts interferon to merge Ribavirin is at present treated C type hepatitis, it is said to reach the effect that doubles.The interferon of another long-acting type (as the pegylated interferon) also develops, and it is to utilize biotechnology that interferon is slowly discharged, and more traditional interferon of its half-life is long ten times and maintain in the sufferer blood, and the number of times that sufferer is gone to a doctor weekly reduces.
The therapeutic modality of present C type hepatitis, adopt interferon therapy that preferable curative effect is arranged more separately with the combination therapy (combanation therapy) that utilizes interferon to merge antiviral drugs Ribavirin, but, the treatment back finds also only to have 18% to reach the persistent virus removing, certainly, if the prolongation interferon no doubt can improve its persistent virus and be scavenged into 30% to year the course of treatment, but burden such as side effects of pharmaceutical drugs and cost, it is intolerable to be still patient institute.With side effects of pharmaceutical drugs:
The side effect of interferon
The injection initial stage: heavy cold such as fever, headache, muscular soreness, Evil heart symptom are arranged, but after one to two week, promptly can disappear.
Late period: can produce that tired, muscular soreness, leukocyte slightly descend, anemia melancholy and anxiety, lather, lose weight and symptom such as lose hair.
The side effect of antiviral drugs Ribavirin: anemia is arranged, cough, scratch where it itches, symptom such as erythema and insomnia.
Summary of the invention
The object of the present invention is to provide a kind of C type hepatitis auxiliary therapeutical agent, this auxiliary therapeutical agent collocation C type hepatitis combination therapy (interferon and Ribavirin), its effect is better than present any therapeutic modality, especially after taking this auxiliary therapeutical agent, the intravital natural killer cell of patient with liver cirrhosis, CD8+ cell, CD4+ cell and CD4+/CD8+ cells ratio obviously increase, IgG, IgA then can reduce, and complement concentration also improves relatively in the serum, and therefore the effect of carrying with patient's immune function is arranged.
The specific embodiment
For achieving the above object, C type hepatitis auxiliary therapeutical agent provided by the invention, comprises with treatment C type hepatitis in order to collocation C type hepatitis combination therapy (interferon and Ribavirin):
The Cordyceps of weight ratio 50 to 90 (Cordyceps sinensis) reaches
The Radix Astragali of weight ratio 10 to 50 (Astragalus memsrancens).
Wherein, Cordyceps refers to China pilose spore (Hirsutella sinensis) the mycelium submerged fermentation culture of its phorozoon.
Wherein, Cordyceps refer to Cordyceps institute's separation and purification and mycelium (strain), comprise:
China's Paecilomyces varioti (Paecilomyces sinensi), Chinese golden spore mould (Chrysosporiumsinense), worm give birth to mycelium submerged fermentation cultures such as bunch spore (Sporothrix insectorum), Stachybotrys atra (Stachybotrys sp.), the curved neck mould (Tolypocladium sp.) of China, the high Paecilomyces varioti of Vespertilio, Hirsutella hepiali Chen et Shen.
Wherein, the preferable weight ratio of Cordyceps is 70 to 80, and Radix Astragali is 20 to 30.
Wherein, the zinc that also comprises weight ratio 5 to 10.
Wherein, comprise: the Radix Astragali of the Cordyceps of weight ratio 75 to 80, weight ratio 10 to 20, and the zinc of weight ratio 5 to 10.
Main component in this auxiliary therapeutical agent and to the pharmacological effect of treatment C type hepatitis, division is as follows:
Cordyceps (Cordyceps sinensis)
Composition: Cordyceps contains many active substances, comprising: amino acid, Polysaccharides (polysaccharide), cordycepin (cordycepin), cordycepic acid (cordycepic acid), lysergol (ergosterol), nucleotides (nucleutide), super oxygen disproportionation ferment (SOD) and trace element (traceelements).Wherein, nucleotides makes cell active, improves function of human body and the ability of resisting the thing that causes a disease naturally.
Pharmacological effect: the pharmacological action of Cordyceps comprise antibiotic, antiinflammatory, analgesic, calm, promote vasodilation, relieving asthma, anti-arrhythmia, enhance metabolism, aging resistance, antitumor (cancer) and immune stimulating activity.Generally be used for eliminating the phlegm more, antitussive, enhancing energy, restore and impotence due to deficiency of the kidney after being ill, also effective in cure in following disease, as: pulmonary tuberculosis, anemia, angina pectoris, nephritis, hepatitis, liver cirrhosis, hypertension, diabetes and multiple treatment of cancer also have example clinically.
In the pharmacological research document, the effect that Cordyceps once was mentioned roughly has in addition: pair cell immunity or humoral immunization, the dual regulation that have inhibition, promotes.Its water extract can promote the thymocyte cell mitosis, directly stimulates the increment of T lymphocyte.With Semen Persicae and with the treatment posthepatitic cirrhosis, can increase the lymphocyte conversion ratio, natural killer cell function, CD4+/CD8+ ratio.It faces upward the effect of system humoral immunization to posthepatitic cirrhosis treatment demonstration, reduces IgG, IgA etc.
Radix Astragali (Astragalus memsrancens)
Composition: Radix Astragali is the root of Duo Nian Sheng Beans section herbaceous plant Radix Astragali, and is of a great variety, formal name used at school: Astragalus memsrancens, popular name: Milk-Vetch Root.Be a kind of southern china herbaceos perennial that is grown in, use the position to be root, the root center is a buff, tastes to have sweet taste.The Radix Astragali medicinal part is a root, is a kind of herbaceos perennial very common, as safe as a house, also is the tonic medicine that the traditional Chinese medical science is widely used for QI invigorating most.The modern science man carries out extensive studies to the pharmacological action and the chemical analysis of Radix Astragali, analyze Radix Astragali and mainly contain polysaccharide, monosaccharide, flavonoid, alkaloid (choline, betanin), several amino acids, glucuronic acid and micro-folic acid etc., reach multiple minor metallic elements such as selenium, silicon.
Pharmacological effect: according to reliable reported in literature, Radix Astragali has become the required important immunity of treatment cancer and these two kinds of diseases of AIDS and has adjusted agent, can support the immune system of having changeed weak, the medical herbs of interferon system in can body as a kind of.In addition, also to add yellow works gradually be one of main composition to health food abroad in recent years, to provide consumer with another selection as the treatment disease of natural goods medicine.With regard to the pharmacological effect of Radix Astragali, learn that through experiment it is aspect the antibody generation: the spleen antigen binding cell (the presoma cell that comprises T cell, B cell) to the immunoreation commitment has the promotion proliferative effect.Normal person or sufferer all there are cycli phosphate gland sweet (cAMP) in the spleen of enhancement, and IgG in the blood, the ability of IgA and IgM.Aspect cellular immunization, to chronic tracheitis, chronic hepatitis patient and the healthy function that the enhancing cellular immunization is arranged per capita.
Radix Astragali has extensively and significant effects immunologic function, the effect that has enhancing or regulate.Prove that in zoopery Radix Astragali can promote the virus induction gamma interferon and suppress virus breeding.
The evaluation of Cordyceps
Cordyceps of the present invention, the generalized mycelium (strain) that has comprised asexual generation institute's separation and purification of alleged in the literature Cordyceps correspondence and got, include: China pilose spore (Hirsutella sinensis), China's Paecilomyces varioti (Paecilomyces sinensi), China's golden spore mould (Chrysosporium sinense), worm gives birth to bunch spore (Sporothrix insectorum), Stachybotrys atra (Stachybotrys sp.), the curved neck mould (Tolypocladium sp.) of China, peacilomyce hepiahi, mycelial submerged fermentation culture such as Hirsutella hepiali Chen et Shen, and alleged Cordyceps is meant China pilose spore (Hirsutella sinensis) in all narration of following the present invention and operation.Though China pilose spore was reported to the phorozoon of Cordyceps in 1989, it is academic the point at issue always.Therefore, whether applicant's United States Patent (USP) power US6251606 and two Cordyceps authenticate technologies of US6271003 by having obtained already are the bioassay of Cordyceps to China pilose spore, and the result confirms that China pilose spore really is the phorozoon of Cordyceps.In addition, other research report is also pointed out, find that by the ITS sequence that compares between them the natural Cordyceps and the genetic distance of China pilose spore are very low (<0.02) (being that likelihood is very high), and and Chinese Paecilomyces varioti (Paecilomyces sinensi), Stachybotrys atra (Stachybotrys sp.), the genetic distance of curved neck mould (Tolypocladium sp.) is big (being that likelihood is low) quite, be respectively 0.34,0.21 and 0.25.Therefore, the present invention selects to represent the object of Cordyceps as operation with China pilose spore.But this selection is not to negate other in view of the above as Chinese Paecilomyces varioti, Stachybotrys atra, the curved neck composition that does not have Cordyceps such as mould, and can't and reach the effect of expection as therapeutic agent component of the present invention.
The toxotest of Cordyceps (China is embraced by hair)
The health food that with Cordyceps is composition has been the main flow in the market, but for making Cordyceps of the present invention after the taking of long-time dosage, unlikely to human body generation harmful effect, especially foot is suffered from the C type hepatitis that immunologic function reduces, therefore, at the toxicity of Cordyceps (Cordyceps sinensis) (China pilose spore), entrust Taiwan Chinese Medicine institute (National Research Institute ofChinese Medicine), carry out the subacute toxicity test.
1, executive mode
Carry out continuous 14 days oral potion every day Cordyceps mycelium water extract of the present invention (Water fractin of Cordyceps MeOH extracts) subacute safe toxicological test.The extract dosage is to be reference index with 10 times of clinical administration dosage, two weeks of potion continuous oral every day, and observation experiment animal (rat) the following situation continuously:
(1). behavior performance (SMA).
(2). the variation of body weight, food and water intake amount.
(3). hematological check: as haemachrome, platelet, erythrocyte, leukocytic classification, and clotting time etc.
(4). blood biochemical is checked 12 inspections of a blood biochemical, as bilirubin, AST, ALT, BUN, Creatinine, glucose, total protein, albumin, K, Na, Ca.
(5). urine biochemical investigation: as settling ratio, protein, electrolyte content, pH value.
(6). organ and tissue slice: the micro-pathological anatomy check of main organs such as the heart, liver, lung, kidney, stomach, gallbladder.
Laboratory animal is taken continuously, Cordyceps mycelium water extract 15 days, after observing statistics, find, to taking relatively did not influence of feedstuff, amount of drinking water, urine amount and matched group, blood mesophytization value shows that the reference value plasma protein of nutrition of whole body standard increases, and relative BUN, protein also increases in the urine, but muroid and human difference one for containing protein in the urine and increasing with the amount of blood plasma, be not because of the caused toxicity phenomenon of medicine.
Can learn that by above result worm summer in winter lead fungi filament water extract of the present invention there is no the influence of subacute toxicity for the laboratory animal rat.
Experimental pre-Clinical
For further verifying the drug effect of auxiliary therapeutical agent of the present invention, the spy cooperates the pre-Clinical of experimentizing property with doctor, with auxiliary therapeutical agent and interferon and Ribavirin combined treatment C type hepatitis, its as a result treatment rate and can effectively improve the various side effect that C type hepatitis uses interferon and Ribavirin near 90%.
All sufferers of being tried are all accepted the deposited interferon and the Ribavirin combined treatment in 24 weeks by a definite date, cost auxiliary therapeutical agent of the present invention or placebo (placebo) again, carry out the double-blind trial (double-blind) of standard, treated for 24 weeks and followed the trail of in addition for 24 weeks again, become the experimental preceding clinical experiment that was total up to for 48 weeks.At whole experimental session, collect blood sample and data.
Began in the 2nd week the sufferer grouping and give experimental group to replenish auxiliary therapeutical agent of the present invention or placebo, merge the Ribavirin treatment in the 24th all interferon and finish, auxiliary therapeutical agent or placebo still continue to provide to finishing in the 48th week.Blood sample and data comprise:
The mutually sharp biochemical numerical value-WBC of blood drawing check, Hemoglobin, Platelet, BUN, Creatinine, SGOT/SGPT, HCV-RNA are qualitative.
Malaise symptoms kind and frequency
Experiment condition that experimental clinical experiment is carried out and result followed are as shown in following:
Experimental pre-Clinical one
1, medicine: 6 months treatment phases, subcutaneous injection Luo Shi Roferon-A (IFN) 300 ten thousand units, 3 times weekly (not having collocation antiviral agents Ribavirin), and, last till that always the mat woven of fine bamboo strips finished in 6 months in treatment phase the 2nd all oral auxiliary therapeutical agents of the present invention of beginning or placebo.
2, experimenter's number: 28 people, all do not accepted interferon therapy, organize into groups at random.
3, " IFN+ auxiliary therapeutical agent " group: 10 people, the simple interferon therapy auxiliary therapeutical agent of the present invention of arranging in pairs or groups.
4, " IPN " group: 18 people, simple interferon therapy collocation placebo.
5, continue virus sweep rate % (SVR): as table 1
Experimental pre-Clinical one result of table 1
Account for the percentage ratio of total experimenter's mouth in the bracket for it
6, conclusion:
(1). add auxiliary therapeutical agent collocation treatment of the present invention, can promote effect of interferon.
(2). add auxiliary therapeutical agent of the present invention collocation treatment, can reduce the recurrence jail after the treatment.
Experimental pre-Clinical two
1, medicine: adopt combination therapy, subcutaneous injection Luo Shi Roferon-A (IFN) 300 ten thousand units 3 times weekly add 1000 milligrams of antiviral agents Ribavirin 2 times weekly.And in treatment phase second all oral auxiliary therapeutical agents of the present invention of beginning or placebo, 6 months altogether treatment phase.
2, experimenter's number: 20 people, all do not accepted interferon therapy, organize into groups at random.
3, " IFN+ auxiliary therapeutical agent " group: 8 people, standard combination therapy collocation auxiliary therapeutical agent.
4, " IFN " group: 12 people, standard combination therapy collocation placebo.
5, continue virus sweep rate % (SVR): as table 2
Experimental pre-Clinical two results of table 2
Account for the percentage ratio of total experimenter's mouth in the bracket for it
6, conclusion:
(1) adds auxiliary therapeutical agent collocation treatment of the present invention, can promote the therapeutic effect of combination therapy (IFN+Ribavirin).
(2) add auxiliary therapeutical agent collocation treatment of the present invention, can reduce the relapse rate after the treatment; 8 are tried among the patient, and 7 states of still keeping the virus safe removing in treatment in back 2 years are arranged.
(3) in this test, add the effect that as if antiviral agents Ribavirin do not improve treatment.
Experimental pre-Clinical three
1, medicine: 6 months treatment phases, subcutaneous injection Luo Shi Roferon-A (IFN) 300 ten thousand units 3 times weekly add 1000 milligrams of antiviral agents Ribavirin 2 times weekly, and in second week of the treatment phase oral auxiliary therapeutical agent of the present invention of beginning or placebo.
2, experimenter's number: 32 people, all do not accepted interferon therapy, organize into groups at random.
3, " IFN+ auxiliary therapeutical agent " group: 16 people, the standard combination therapy auxiliary therapeutical agent of the present invention of arranging in pairs or groups.
4, " IFN " group: 16 people, standard combination therapy collocation placebo.
5. continue virus sweep rate % (SVR): as table 3
Experimental pre-Clinical three results of table 3
Account for the percentage ratio of total experimenter's mouth in the bracket for it
Side effect relatively when 6, treating
Side effect " IFN+ auxiliary therapeutical agent " group number " IFN " group number
The melancholy irritability insomnia of the slight alopecia erythema of fever, headache, the unusual eye movement of the tired arthralgia of the DOMS anaemia 10g/dl<ferroheme<11g/dl 9g/dl<ferroheme<10g/dl ferroheme<9g/dl that loses weight ??13(83%) ??12(75%) ??13(83%) ??10(63%) ??9(56%) ??11(69%) ??10(63%) ??2(13%) ??12(75%) ??9(56%) ? ??5(31%) ??1(6%) ??1(6%) ??14(90%) ??12(75%) ??12(75%) ??13(83%) ??10(63%) ??11(69%) ??11(69%) ??3(19%) ??13(83%) ??14(90%) ? ??9(56%) ??2(13%) ??0(0%)
Leukopenia 3,000/UL<leukocyte<3,500/UL 2,500/UL<leukocyte<3,000/UL leukocyte<2,500/UL ? ?3(19%) ?0(0%) ?3(19%) ??5(31%) ??0(0%) ??1(6%)
Represent it to account for the percentage ratio of total experimenter's mouth in the bracket
7, conclusion:
(1) adds auxiliary therapeutical agent collocation combination therapy of the present invention (IFN+Ribavirin) treatment, represented the effect that viral clearance rate promotes, also reduced relapse rate simultaneously.
(2) in the side effect in when treatment, that group that adds auxiliary therapeutical agent of the present invention is arranged, unusual ocular movement, lose weight, side effect such as haemachrome and leukocyte cell minimizing, the situation of slowing down is all arranged.
By above-mentioned various experimental results and data as can be known, the C type treating hepatitis mode that auxiliary therapeutical agent of the present invention can be arranged in pairs or groups present really, and can effectively increase its curative effect, and alleviate the side effect of sufferer when treatment.
Mainly formed as above-mentioned C type hepatitis auxiliary therapeutical agent of the present invention, yet in the implementation process of reality, still can be added other micro-elements to increase its therapeutic effect to C type treating hepatitis by Cordyceps, Radix Astragali.For example, zinc (Zinc) element that in C type hepatitis auxiliary therapeutical agent of the present invention, adds trace, can replenish the zinc that is run off in the C type hepatitis body, and zinc element just has direct relation for human immunocyte's's (T cell) generation from the beginning, therefore, zinc is incorporated in the C type hepatitis auxiliary therapeutical agent of the present invention immunocyte that can the hypertrophy patient and reach the effect that promotes immunologic function.The about 5-10 of weight ratio of the trace zinc element of this adding.Above-mentioned zinc element replenishes, also can be in other way, and non-being unique embodiment in the direct adding C type of the present invention hepatitis auxiliary therapeutical agent.

Claims (5)

1, a kind of C type hepatitis auxiliary therapeutical agent comprises: the Radix Astragali of the Cordyceps China pilose spore of weight ratio 50 to 90 and weight ratio 10 to 50; This C type hepatitis auxiliary therapeutical agent in order to collocation C type hepatitis combination therapy interferon and Ribavirin with treatment C type hepatitis.
2, C type hepatitis auxiliary therapeutical agent as claimed in claim 1 is characterized in that, Cordyceps refers to the Hirsutella sinensis mycelium submerged fermentation culture of its phorozoon.
3, C type hepatitis auxiliary therapeutical agent as claimed in claim 1 is characterized in that the weight ratio of Cordyceps is 70 to 80, and Radix Astragali is 20 to 30.
4, C type hepatitis auxiliary therapeutical agent as claimed in claim 1 is characterized in that, also comprises the zinc of weight ratio 5 to 10.
5, C type hepatitis auxiliary therapeutical agent as claimed in claim 4 is characterized in that, comprises: the Radix Astragali of the Cordyceps China pilose spore of weight ratio 75 to 80, weight ratio 10 to 20, and the zinc of weight ratio 5 to 10.
CN 200310101281 2003-10-16 2003-10-16 Auxiliary therapeutic agent for C type hepatitis CN1274363C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200310101281 CN1274363C (en) 2003-10-16 2003-10-16 Auxiliary therapeutic agent for C type hepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200310101281 CN1274363C (en) 2003-10-16 2003-10-16 Auxiliary therapeutic agent for C type hepatitis

Publications (2)

Publication Number Publication Date
CN1607003A CN1607003A (en) 2005-04-20
CN1274363C true CN1274363C (en) 2006-09-13

Family

ID=34756159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200310101281 CN1274363C (en) 2003-10-16 2003-10-16 Auxiliary therapeutic agent for C type hepatitis

Country Status (1)

Country Link
CN (1) CN1274363C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722056B2 (en) 2003-10-03 2014-05-13 Tcm Biotech International Corp. Methods for making and compositions comprising fermentation products of cordyceps sinensis
GB2439046B (en) * 2006-06-16 2010-12-08 Phynova Ltd Antiviral product
GB2455151A (en) * 2007-11-27 2009-06-03 Phynova Ltd An Astragalus extract as an antiviral for several genera of the Flaviviridae family
TWI554277B (en) * 2012-03-28 2016-10-21 泰宗生物科技股份有限公司 Pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease

Also Published As

Publication number Publication date
CN1607003A (en) 2005-04-20

Similar Documents

Publication Publication Date Title
CN1295982C (en) Fish growth promoting prepn. made up of Chinese herb medicines
CN100360178C (en) Antisenescence medicine
CN100346796C (en) Phy siologically active substance EEM-S originating in mushrooms, process for producing same and drugs
CN102349975B (en) Health care product formula of dendrobium officinale, composition as well as preparation method and application of composition
CN103735825B (en) Comprehensively regulating Chinese medicine composition and application thereof
CN102266379B (en) Liquid preparation for strengthening tendons and bones, relaxing tendons, activating collaterals and relieving arthralgia due to wind-dampness and aching pain of waist and knees and preparation method thereof
KR20010020586A (en) Herbal extract composition and method with immune-boosting capability
CN1228074C (en) Chinese traditional medicine for treating immune hypofunction and disfunction
CN1943771A (en) The pharmaceutical for treatment of vascular lesion through actions on the NEI network
CN102884079B (en) Compositions and methods for treating hepatitis virus infection
CN103750339B (en) Saussurea involucrate culture health-care food and application thereof
CN103621869B (en) Giant salamander oligosaccharide peptide health-care product
CN1472220A (en) Triterpene extracts from achyranthes roots and their use in medicine against osteoporosis
CN1301666C (en) Health food capable of raising immunity and its production process
CN100381165C (en) Medication for improving sleep
CN1569884B (en) Method for preparing astragaloside and its use in preparation of drug for preventing and treating diabetic nephropathy
CN1762236A (en) Health-caring product capable of increasing human immunity and its preparation method
CN1256133C (en) Antifatigue Chinese medicine composition and its prepn process
CN1891240A (en) Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method
CN101020719A (en) Composite angelica polysaccharide and its prepn process and use
CN103479683A (en) North cordyceps sinensis sporophores cultivated in large scale and health care and pharmaceutical application thereof
CN101716256B (en) Preparation used for strengthening immunity
CN105521302A (en) Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus
CN1478508A (en) Chinese medicinal composition for treating fatty liver and its preparation method
CN1853506A (en) Health-care food for improving human immunity and production thereof

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060913

Termination date: 20161016

CF01 Termination of patent right due to non-payment of annual fee